Raymond James & Associates Increases Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Raymond James & Associates lifted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 22.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 4,593 shares of the company’s stock after purchasing an additional 851 shares during the period. Raymond James & Associates’ holdings in TransMedics Group were worth $363,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Cutler Group LLC CA lifted its position in shares of TransMedics Group by 600.0% in the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock worth $38,000 after purchasing an additional 600 shares during the period. Global Retirement Partners LLC purchased a new stake in shares of TransMedics Group in the 3rd quarter worth approximately $38,000. RiverPark Advisors LLC purchased a new stake in shares of TransMedics Group in the 3rd quarter worth approximately $60,000. Van ECK Associates Corp lifted its position in shares of TransMedics Group by 39.0% in the 3rd quarter. Van ECK Associates Corp now owns 2,127 shares of the company’s stock worth $116,000 after purchasing an additional 597 shares during the period. Finally, Yarbrough Capital LLC purchased a new stake in shares of TransMedics Group in the 4th quarter worth approximately $201,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on TMDX. Piper Sandler began coverage on shares of TransMedics Group in a research report on Thursday, March 28th. They set an “overweight” rating and a $95.00 target price for the company. Oppenheimer increased their target price on shares of TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a research report on Tuesday, February 27th. JPMorgan Chase & Co. increased their target price on shares of TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Finally, Morgan Stanley increased their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $102.00.

Insiders Place Their Bets

In other TransMedics Group news, CEO Waleed H. Hassanein sold 4,000 shares of the firm’s stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $95.12, for a total value of $380,480.00. Following the completion of the transaction, the chief executive officer now owns 74,087 shares of the company’s stock, valued at $7,047,155.44. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, CEO Waleed H. Hassanein sold 4,000 shares of the stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $95.12, for a total value of $380,480.00. Following the sale, the chief executive officer now owns 74,087 shares in the company, valued at $7,047,155.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Waleed H. Hassanein sold 12,000 shares of the stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the completion of the sale, the chief executive officer now owns 74,087 shares in the company, valued at approximately $7,044,932.83. The disclosure for this sale can be found here. Over the last quarter, insiders sold 117,078 shares of company stock valued at $9,972,971. Insiders own 6.70% of the company’s stock.

TransMedics Group Trading Up 3.2 %

NASDAQ TMDX opened at $92.08 on Friday. The company has a fifty day simple moving average of $82.98 and a two-hundred day simple moving average of $74.69. The stock has a market cap of $3.01 billion, a P/E ratio of -119.58 and a beta of 1.99. TransMedics Group, Inc. has a 12-month low of $36.42 and a 12-month high of $99.63. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. The business had revenue of $81.20 million during the quarter, compared to analysts’ expectations of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The business’s quarterly revenue was up 158.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.21) earnings per share. On average, analysts forecast that TransMedics Group, Inc. will post -0.14 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.